Articles

Resource utilization associated with the management of potential interactions between direct-acting antivirals for chronic hepatitis C treatment and cardiovascular and central nervous system drugs

Evaluation of the additional actions and resource utilization required for the management of potential drug-drug interactions in HCV patients showing cardiovascular and central nervous system comorbidities, treated with sofosbuvir/velpatasvir compared to glecaprevir/ pibrentasvir in routine clinical practice in Spain.


Download PDF
Skip to content